242 related articles for article (PubMed ID: 36701102)
1. Gangliosides as Siglec ligands.
Schnaar RL
Glycoconj J; 2023 Apr; 40(2):159-167. PubMed ID: 36701102
[TBL] [Abstract][Full Text] [Related]
2. Ganglioside binding pattern of CD33-related siglecs.
Rapoport E; Mikhalyov I; Zhang J; Crocker P; Bovin N
Bioorg Med Chem Lett; 2003 Feb; 13(4):675-8. PubMed ID: 12639556
[TBL] [Abstract][Full Text] [Related]
3. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
Linnartz-Gerlach B; Mathews M; Neumann H
Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
[TBL] [Abstract][Full Text] [Related]
4. The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells.
Tsubata T
Int Immunol; 2023 Oct; 35(10):461-473. PubMed ID: 37504378
[TBL] [Abstract][Full Text] [Related]
5. Myelin-associated glycoprotein (Siglec-4) expression is progressively and selectively decreased in the brains of mice lacking complex gangliosides.
Sun J; Shaper NL; Itonori S; Heffer-Lauc M; Sheikh KA; Schnaar RL
Glycobiology; 2004 Sep; 14(9):851-7. PubMed ID: 15175257
[TBL] [Abstract][Full Text] [Related]
6. Glycan Chains of Gangliosides: Functional Ligands for Tissue Lectins (Siglecs/Galectins).
Ledeen RW; Kopitz J; Abad-Rodríguez J; Gabius HJ
Prog Mol Biol Transl Sci; 2018; 156():289-324. PubMed ID: 29747818
[TBL] [Abstract][Full Text] [Related]
7. Human sialoglycan ligands for immune inhibitory Siglecs.
Gonzalez-Gil A; Li TA; Kim J; Schnaar RL
Mol Aspects Med; 2023 Apr; 90():101110. PubMed ID: 35965135
[TBL] [Abstract][Full Text] [Related]
8. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
9. The role of sialic acid-binding immunoglobulin-like-lectin-1 (siglec-1) in immunology and infectious disease.
Prenzler S; Rudrawar S; Waespy M; Kelm S; Anoopkumar-Dukie S; Haselhorst T
Int Rev Immunol; 2023; 42(2):113-138. PubMed ID: 34494938
[TBL] [Abstract][Full Text] [Related]
10. Siglecs in Brain Function and Neurological Disorders.
Siddiqui SS; Matar R; Merheb M; Hodeify R; Vazhappilly CG; Marton J; Shamsuddin SA; Al Zouabi H
Cells; 2019 Sep; 8(10):. PubMed ID: 31546700
[TBL] [Abstract][Full Text] [Related]
11. Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties.
Yu H; Gonzalez-Gil A; Wei Y; Fernandes SM; Porell RN; Vajn K; Paulson JC; Nycholat CM; Schnaar RL
Glycobiology; 2017 Jul; 27(7):657-668. PubMed ID: 28369504
[TBL] [Abstract][Full Text] [Related]
12. Enhanced binding of the neural siglecs, myelin-associated glycoprotein and Schwann cell myelin protein, to Chol-1 (alpha-series) gangliosides and novel sulfated Chol-1 analogs.
Collins BE; Ito H; Sawada N; Ishida H; Kiso M; Schnaar RL
J Biol Chem; 1999 Dec; 274(53):37637-43. PubMed ID: 10608819
[TBL] [Abstract][Full Text] [Related]
13. Discovery, classification, evolution and diversity of Siglecs.
Angata T; Varki A
Mol Aspects Med; 2023 Apr; 90():101117. PubMed ID: 35989204
[TBL] [Abstract][Full Text] [Related]
14. Siglec-7 undergoes a major conformational change when complexed with the alpha(2,8)-disialylganglioside GT1b.
Attrill H; Imamura A; Sharma RS; Kiso M; Crocker PR; van Aalten DM
J Biol Chem; 2006 Oct; 281(43):32774-83. PubMed ID: 16895906
[TBL] [Abstract][Full Text] [Related]
15. Siglec Ligands.
Gonzalez-Gil A; Schnaar RL
Cells; 2021 May; 10(5):. PubMed ID: 34065256
[TBL] [Abstract][Full Text] [Related]
16. Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice.
Pan B; Fromholt SE; Hess EJ; Crawford TO; Griffin JW; Sheikh KA; Schnaar RL
Exp Neurol; 2005 Sep; 195(1):208-17. PubMed ID: 15953602
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
18. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
19. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins.
Bornhöfft KF; Goldammer T; Rebl A; Galuska SP
Dev Comp Immunol; 2018 Sep; 86():219-231. PubMed ID: 29751010
[TBL] [Abstract][Full Text] [Related]
20. Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease.
Gonzalez-Gil A; Porell RN; Fernandes SM; Maenpaa E; Li TA; Li T; Wong PC; Aoki K; Tiemeyer M; Yu ZJ; Orsburn BC; Bumpus NN; Matthews RT; Schnaar RL
J Biol Chem; 2022 Jun; 298(6):101960. PubMed ID: 35452678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
